



Current report in accordance with the provisions of ASF Regulation No. 5/2018, Article 234, letter y) regarding issuers of financial instruments and market operations

Date of report: 03.10.2025

Name of issuing entity: Societatea Nationala NUCLEARELECTRICA S.A.

Headquarters: Bulevardul Iancu de Hunedoara 48, Bucharest

Phone/fax number: 021-203.82.00 / 021 – 316.94.00

Single Code of Registration with the Office of the Trade Register: 10874881

Number of registration with the Trade Register: J1998007403409

Share capital subscribed and paid up: 3,016,438,940

Regulated market the issued securities are traded on: Bucharest Stock Exchange

**To: Bucharest Stock Exchange
Financial Supervisory Authority**

Important event to report: Signing of the Isotope Irradiation Service Agreement between SNN and Framatome GmbH

SN Nuclearelectrica SA announces to shareholders and investors the signing of the Isotope Irradiation Service Agreement between SNN and Framatome GmbH, regarding the development of the IRIS (Innovative Romanian Isotope System) Project for the production of medical radioisotopes using Framatome GmbH's patented technology, following the approval of this agreement by EGMS Decision No. 8/03.09.2025.

The purpose of the Agreement is to establish the terms and conditions of cooperation between Framatome GmbH and SNN regarding the implementation of the Lu-177 medical radioisotope production project at CNE Cernavoda, the operation of the equipment and infrastructure resulting from the implementation of this project, and the development of other projects related to the production of medical radioisotopes in the future.

For the first project—the production of Lu-177 radioisotopes (the IRIS Project), the parties plan to complete the development, installation, and commissioning of a system based on Framatome GmbH technology at Unit 2 of CNE Cernavoda. The project involves the installation of equipment in the Unit 2 reactor during the planned shutdown, estimated for May 2027.

The project is in Phase 1, which began in 2024 and is scheduled for completion this year and within which, to date, the following activities have been carried out, based on the corporate approvals obtained:

- ✓ Conclusion, on October 8, 2024, of the Agreement on the general terms of cooperation between Framatome and SNN "Heads of Terms Agreement for an Irradiation Service Agreement between Framatome and SNN" (the Agreement);
- ✓ General project management activities, aimed at establishing the framework for the project, determining the execution plan, and developing the project schedule;
- ✓ Engineering activities - development of the conceptual engineering design;
- ✓ Contracting of services for the performance of nuclear safety analyses.

The final stage of the first phase involves the conclusion of the Isotope Irradiation Service Agreement (ISA) (the Agreement).

With regard to the costs associated with the implementation of the IRIS project, the parties have agreed that these will be borne by Framatome GmbH. Subsequently, the direct costs related to the operation of the

Societatea Nationala NUCLEARELECTRICA S.A.

Iancu de Hunedoara Boulevard 48, Bucharest 011745, Romania; Tel +4021 203 82 00, Fax +4021 316 94 00;

National Trade Register Office J1998007403409, European Unique Identifier ROONRC.J1998007403409, Unique Registration Code at the Trade Register Office (URC) 10874881, Fiscal Registration Code (CIF) RO10874881, IBAN code RO94 RNCB 0072 0497 1852 0001 opened at BCR

1st District Branch;

Paid and subscribed capital: 3.016.438.940 lei.

office@nuclearelectrica.ro, www.nuclearelectrica.ro

system will be borne by Framatome GmbH, and the indirect costs related to the operation of the system will be borne by SNN. Framatome GmbH will recover the costs associated with the investment from the total value of the final sales.

Thus, the main commercial aspect concerns the payment by Framatome GmbH to SNN of an irradiation tariff for the quantity of Curie (Ci) sold, calculated as a percentage of total sales, depending on production and the year in which it will be recorded.

Framatome GmbH will promote and sell medical radioisotopes to customers, guaranteeing starting with the second year of commercial operation of the IRIS system, priority access for SNN (equivalent to 4,000 doses of Lu-177 treatments per year, at market conditions) for drug manufacturers intending to supply Lu-177 treatments to hospitals and clinics in Romania, under certain conditions.

Framatome GmbH will also allocate, free of charge, irradiation doses equivalent to at least 20 treatments per year, through appropriate mechanisms, partnerships, and non-profit organizations, contributing to global access to modern nuclear medicine for countries such as Romania.

In addition to the financial benefits recorded by SNN, the social benefits brought about by the implementation of the project are essential and demonstrate the vital role of nuclear technology in nuclear medicine, beyond energy production. Thus, the implementation of this project marks an important milestone in the evolution of Nuclearelectrica, offering tangible benefits in the field of healthcare.

CEO

Cosmin GHITA